U.S. Stem Cell
U.S. Stem Cell, Inc. is a leader in regenerative medicine and cellular therapy, focusing on the discovery, development, and commercialization of cell-based therapeutics to treat various diseases and injuries. The company is involved in research, physician training, and the development of proprietary stem cell products, with a mission to improve patient quality of life and reduce healthcare costs through innovative treatments. It has a strong focus on developing proprietary, physician-based stem cell therapies and regenerative medicine solutions, including stem cell banking, veterinary stem cell training, and the creation and management of stem cell clinics. The company emphasizes its pioneering research, extensive training programs, and its commitment to advancing regenerative medicine globally.
Industries
Nr. of Employees
small (1-50)
U.S. Stem Cell
Products
Autologous muscle-derived myoblast cell therapy (cardiac)
Autologous muscle stem cell therapy produced by isolating muscle-derived myoblasts from a patient, expanding them ex vivo, and delivering them to cardiac scar tissue via catheter-based injection to improve cardiac function.
Gene-modified autologous cell therapy expressing angiogenic proteins
Autologous myoblasts modified with an adenoviral vector to express stromal-derived factor to enhance recruitment of endogenous stem cells and angiogenesis in damaged myocardium.
Adipose-derived autologous cell therapy
Therapy using stem cells isolated from patient adipose tissue processed to obtain a therapeutically active cell fraction for endocardial implantation or other administration routes.
Autologous muscle-derived myoblast cell therapy (cardiac)
Autologous muscle stem cell therapy produced by isolating muscle-derived myoblasts from a patient, expanding them ex vivo, and delivering them to cardiac scar tissue via catheter-based injection to improve cardiac function.
Gene-modified autologous cell therapy expressing angiogenic proteins
Autologous myoblasts modified with an adenoviral vector to express stromal-derived factor to enhance recruitment of endogenous stem cells and angiogenesis in damaged myocardium.
Adipose-derived autologous cell therapy
Therapy using stem cells isolated from patient adipose tissue processed to obtain a therapeutically active cell fraction for endocardial implantation or other administration routes.
Services
In-person and online educational courses, hands-on clinical application training and certification for healthcare professionals delivering autologous cell therapies.
Clinical delivery of autologous cell procedures in physician-run clinics, including patient assessment, cell isolation, and administration.
Commercial supply of kits and consumables designed for collection, processing, and administration of autologous cell therapies for human and veterinary use.
Storage and expansion of patient-derived tissues and cells in a registered tissue bank for potential future therapeutic use.
In-person and online educational courses, hands-on clinical application training and certification for healthcare professionals delivering autologous cell therapies.
Clinical delivery of autologous cell procedures in physician-run clinics, including patient assessment, cell isolation, and administration.
Commercial supply of kits and consumables designed for collection, processing, and administration of autologous cell therapies for human and veterinary use.
Storage and expansion of patient-derived tissues and cells in a registered tissue bank for potential future therapeutic use.
Expertise Areas
- Autologous cell therapy development
- Clinical trial management and execution
- Cell culture and ex vivo expansion processes
- Gene-modified cell therapy research
Key Technologies
- Autologous stromal vascular fraction (SVF) isolation
- Adipose-derived cell isolation workflows
- Bone marrow-derived cell isolation
- Cell expansion and GMP-compatible culture systems
News & Updates
A legal case where a federal judge ruled in favor of U.S. Stem Cell, affirming that their procedures are not regulated as drugs by the FDA.
Mark Borman has been appointed Chairman, bringing extensive experience in growth and finance.
The company is expanding its veterinary division to include pet care, wellness, and geriatric services.
The company reported a 21% increase in revenue for 2018, reaching $6.7 million, and a gross profit margin increase of 26%.
U.S. Stem Cell was recognized for rapid growth in North America based on revenue increase from 2015 to 2018.
A legal case where a federal judge ruled in favor of U.S. Stem Cell, affirming that their procedures are not regulated as drugs by the FDA.
Mark Borman has been appointed Chairman, bringing extensive experience in growth and finance.
The company is expanding its veterinary division to include pet care, wellness, and geriatric services.
The company reported a 21% increase in revenue for 2018, reaching $6.7 million, and a gross profit margin increase of 26%.
U.S. Stem Cell was recognized for rapid growth in North America based on revenue increase from 2015 to 2018.